2. Search Result
Search Result
Results for "

plasma lipids

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

1

MCE Kits

2

Inhibitory Antibodies

7

Natural
Products

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99194
    Evinacumab

    REGN1500

    		 ANGPTL Others Cardiovascular Disease Metabolic Disease
    Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
    Evinacumab
  • HY-W134326
    Polydextrose

    		Biochemical Assay Reagents Metabolic Disease Cancer
    Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .
    Polydextrose
  • HY-113168
    Butyrylcarnitine

    		Endogenous Metabolite Others
    Butyrylcarnitine is a metabolite in plasma, acts as a biomarker to improve the diagnosis and prognosis of heart failure, and is indicative of anomalous lipid and energy metabolism.
    Butyrylcarnitine
  • HY-129467
    (Rac)-Idroxioleic acid

    2-Hydroxyoleic acid; 2-OHOA

    		 Apoptosis Cancer
    (Rac)-Idroxioleic acid (2-Hydroxyoleic acid) is a synthetic oleic acid (OA) derivative that binds to the plasma membrane and alters lipid organization. (Rac)-Idroxioleic acid has anti-tumor effect .
    (Rac)-Idroxioleic acid
  • HY-W020798
    1-Palmitoyl-2-[3-(diphenylhexatriene)propanoyl]-sn-phosphatidylcholine

    		Fluorescent Dye Others
    1-Palmitoyl-2-[3-(diphenylhexatriene)propanoyl]-sn-phosphatidylcholine is a fluorescent probe with a polar phosphatidylethanolamine head group for the determination of surface lipid oxidation in lipoproteins and plasma .
    1-Palmitoyl-2-[3-(diphenylhexatriene)propanoyl]-sn-phosphatidylcholine
  • HY-113168R
    Butyrylcarnitine (Standard)

    		Endogenous Metabolite Others
    Butyrylcarnitine (Standard) is the analytical standard of Butyrylcarnitine. This product is intended for research and analytical applications. Butyrylcarnitine is a metabolite in plasma, acts as a biomarker to improve the diagnosis and prognosis of heart failure, and is indicative of anomalous lipid and energy metabolism.
    Butyrylcarnitine (Standard)
  • HY-155789
    C17 Globotriaosylceramide (d18:1/17:0)

    Ceramide trihexoside (d18:1/17:0); Gb3(d18:1)(C17:0)

    		 Others Others
    C17 Globotriaosylceramide (d18:1/17:0) is a sphygosine lipid that can be used to quantify Globotriaosylceramide in plasma and urine of patients with Fabry disease by gas chromatography-mass spectrometry (GC-MS) .
    C17 Globotriaosylceramide (d18:1/17:0)
  • HY-W414069
    Thiocholesterol

    		Endogenous Metabolite Liposome Others
    Thiocholesterol is a member of the class of cholesteric liquid crystals (CLCs) that can be used to synthesis cationic lipid. Thiocholesterol is a stronger stabilizer of silver nanoparticles (SNPs). Thiocholesterol can be used for plasma membrane research and drug delivery .
    Thiocholesterol
  • HY-134939
    thio-Miltefosine

    		Others Others
    thio-Miltefosine is a modulator of rafts in membrane tissue. Rafts are nanoscale aggregates of different lipids and proteins that profoundly affect cellular function. Thio-Miltefosine modulates membrane phase behavior on cell-derived giant plasma membrane vesicles .
    thio-Miltefosine
  • HY-106818A
    Monatepil maleate

    AJ-2615

    		 Acyltransferase Calcium Channel Cardiovascular Disease Metabolic Disease
    Monatepil maleate (AJ-2615) is a potent and orally active Ca 2+-channel antagonist and a noncompetitive ACAT inhibitor. Monatepil maleate decreases blood pressure and improves plasma lipid metabolism. Monatepil maleate has the potential for the research of hyperlipidemia .
    Monatepil maleate
  • HY-157639A
    18:2 Lyso PA sodium

    		Others Cardiovascular Disease
    18:2 Lyso PA sodium is an unsaturated lysophosphatidic acid (LysoPA), a lipid mediator mainly present in plasma and thought to be involved in the pathogenesis of acute coronary syndrome (ACS). 18:2 Lyso PA sodium significantly correlates with serum autotaxin (ATX) in peripheral arteries .
    18:2 Lyso PA sodium
  • HY-165119
    1-Stearoyl-2-eicosapentaenoyl-sn-glycero-3-PE

    PE(18:0/20:5); 18:0/20:5-PE

    		 Others Others
    1-Stearoyl-2-eicosapentaenoyl-sn-glycero-3-PE (PE(18:0/20:5)) is a phospholipid identified in plasma lipid profile analysis, with similar lipid level changes in high-grade cervical intraepithelial neoplasia and cervical cancer compared with normal state and low-grade cervical intraepithelial neoplasia, and can be used to monitor cervical cancer progression.
    1-Stearoyl-2-eicosapentaenoyl-sn-glycero-3-PE
  • HY-16620
    DF 461

    		Others Metabolic Disease
    DF 461 is a sterol synthase inhibitor with significant inhibitory activity. DF 461 shows high selectivity for the liver and can effectively inhibit cholesterol synthesis in rat liver. DF 461 has shown the effect of lowering plasma lipids in repeated dosing studies in non-rodents .
    DF 461
  • HY-149120
    ASM-IN-1

    		Phospholipase Cardiovascular Disease Inflammation/Immunology
    ASM-IN-1 is a potent and orally active acid sphingomyelinase (ASM) inhibitor with an IC50 value of 1.5 µM. ASM-IN-1 reduces lipid plaques in the aortic arch and aorta and reduces plasma ceramide concentration and Ox-LDL levels. ASM-IN-1 shows antiatherosclerotic and anti-inflammatory activity .
    ASM-IN-1
  • HY-130323
    13-HPOT

    		Bacterial Infection
    13-HPOT, a linolenic fatty acid hydroperoxide, is an antibacterial agent. 13-HPOT has a strong dose response effect on three plant pathogen gram negative bacteria: Pectobacterium carotovorum, Pseudomonas syringae and Xanthomonas translucens. 13-HPOT can interact with the lipid representative of the inner bacterial plasma membrane .
    13-HPOT
  • HY-123341
    9-OxoODE

    9-KODE

    		 Endogenous Metabolite Metabolic Disease
    9-OxoODE results from oxidation of the allylic hydroxyl of either 9(S)- or 9(R)-HODE. Rabbit reticulocyte plasma and mitochondrial membranes contain both 9- and 13-oxoODEs, representing about 2% of the total linoleate residues in the membranes. Most of these oxidized linoleate residues are esterified to membrane lipids.
    9-OxoODE
  • HY-156004
    Ziapin 2

    		Others Others
    Ziapin 2 is a molecular optomechanical light transducer. Ziapin 2 is an amphiphilic azobenzene with a strong non-covalent affinity to the plasma membrane. Ziapin 2 can be used to photo-modulate the membrane potential in cells of the Gram-positive bacterium Bacillus subtilis. Ziapin 2 enters the lipid membrane very rapidly (≈ 40 ns) .
    Ziapin 2
  • HY-17409
    Nystatin
    Maximum Cited Publications
    25 Publications Verification

    		 Fungal Antibiotic Apoptosis Bacterial Infection
    Nystatin is an orally active polyene antifungal antibiotic effective against yeast and mycoplasma. Nystatin increases the permeability of plasma membranes to small monovalent ions, including chloridion . Nystatin is a cholesterol-sequestering agent , partially prevents Oxaliplatin-induced lipid raft aggregation, DR4 and DR5 clustering, and thereby reduces apoptosis .
    Nystatin
  • HY-P99822
    Recaticimab

    SHR-1209

    		 PCSK9 Metabolic Disease
    Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Recaticimab can bind to PCSK9 and mediate its degradation, increasing the level of low-density lipoprotein (LDL) receptors on the surface of liver cells, reducing the level of LDL in plasma, thereby lowering blood lipids. Recaticimab can be used for the study of hypercholesterolemia .
    Recaticimab
  • HY-119088
    Estrogen receptor modulator 12

    		Others Others
    Estrogen receptor modulator 12 (compound 1a-(R)) is a selective estrogen receptor modulator with estrogen agonist and antagonist activities in in vivo models. Estrogen receptor modulator 12 exhibits antagonist effects on the uterus and estrogen agonist activities on bone, plasma lipids, hot flashes, and vagina in in vivo models, and is a potential compound for suppressing postmenopausal symptoms.
    Estrogen receptor modulator 12
  • HY-139040
    2-(Tetradecylthio)acetic acid

    		PPAR Metabolic Disease
    2-Tetradecylthio acetic acid is a pan-peroxisome proliferator activated receptor (pan-PPAR) activator. 2-Tetradecylthio acetic acid induces hypolipidemia. 2-Tetradecylthio acetic acid reduces plasma lipids and enhances hepatic fatty acid oxidation in rodents. 2-Tetradecylthio acetic acid increases the expression of genes involved in fatty acid uptake, activation, accumulation, and oxidation .
    2-(Tetradecylthio)acetic acid
  • HY-117912
    TRC210258

    		Others Cardiovascular Disease
    TRC210258 is a TGR5 agonist with activity to improve diabetes-associated hyperglycemia and dyslipidemia. TRC210258 promotes energy expenditure by enhancing the release of glucagon-like peptide-1. TRC210258 is able to improve glucose metabolic control in high-fat diet-induced obese mice. TRC210258 also showed improvement in lipid parameters in high-fat-fed hamsters, including reductions in plasma triglyceride and low-density lipoprotein cholesterol levels. TRC210258 improved emerging lipid-related cardiovascular risk parameters including remnant cholesterol and triglyceride clearance .
    TRC210258
  • HY-100313A
    YM-53601
    2 Publications Verification

    		 Farnesyl Transferase HCV Infection Metabolic Disease
    YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
    YM-53601
  • HY-161892
    FABP4-IN-4

    		FABP Metabolic Disease Inflammation/Immunology
    FABP4-IN-4 (Compound 30) is an orally active inhibitor for FABP, with IC50 of 1.18 μM for FABP 1. FABP4-IN-4 improves the glucose tolerance, reduces the level of blood glucose, plasma lipids and hepatic inflammatory factors, attenuates hepatic steatosis, and exhibits anti-inflammatory effects in mouse diet-induced obesity models .
    FABP4-IN-4
  • HY-106808
    Cerebrocrast

    IOS-1.1212

    		 Calcium Channel Chloride Channel Neurological Disease
    Cerebrocrast (IOS-1.1212) is a 1,4-dihydropyridine (DHP) derivative. Cerebrocrast has a high affinity for the membrane lipid bilayer and it can easily penetrate the blood-brain barrier and incorporate into the plasma and organelle membranes, including those of mitochondria. Cerebrocrast promotes the cotransport of H+ and Cl- in rat liver mitochondria. Cerebrocrast also exhibits neuroprotective and cognition enhancer properties .
    Cerebrocrast
  • HY-100313
    YM-53601 free base

    		Farnesyl Transferase HCV Metabolic Disease
    YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
    YM-53601 free base
  • HY-17409R
    Nystatin (Standard)

    		Fungal Antibiotic Apoptosis Bacterial Infection
    Nystatin (Standard) is the analytical standard of Nystatin. This product is intended for research and analytical applications. Nystatin is an orally active polyene antifungal antibiotic effective against yeast and mycoplasma. Nystatin increases the permeability of plasma membranes to small monovalent ions, including chloridion . Nystatin is a cholesterol-sequestering agent , partially prevents Oxaliplatin-induced lipid raft aggregation, DR4 and DR5 clustering, and thereby reduces apoptosis .
    Nystatin (Standard)
  • HY-124399
    N-Octadecyl-N'-propyl-sulfamide

    		Endogenous Metabolite PPAR Metabolic Disease
    Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating lipid and glucose metabolism, and oleoylethanolamide (OEA) is a natural ligand for PPARα. N-Octadecyl-N'-propyl-sulfamide is an analog of OEA and a potent activator of PPARα, with selective binding affinity for PPARα (EC50=100 nM, compared to 120 nM for OEA). N-Octadecyl-N'-propyl-sulfamide (10 mg/kg; ip) inhibits food intake and reduces body weight gain in rats. At a dose of 1 mg/kg, N-Octadecyl-N'-propyl-sulfamide induces satiety, thereby reducing food intake, body weight, and plasma triglyceride concentrations in free-feeding Wistar rats and obese Zucker (fa/fa) rats.
    N-Octadecyl-N'-propyl-sulfamide
  • HY-W747597
    Ganglioside GD1b Disodium Salt (Bovine Brain)

    Disialoganglioside GD1b; Ganglioside C1; Ganglioside G2

    		 Endogenous Metabolite Cardiovascular Disease
    Ganglioside GD1b is an acidic glycosphingolipid that contains two sialic acid residues linked to an inner galactose unit. It is a component of plasma membranes where it packs densely with cholesterol to form lipid microdomains that modulate both intra- and intercellular signaling events. The concentration of ganglioside GD1b in human brain increases with age, constituting 7.85% of total sialic acid in the brain of 0- to 10-year-old subjects and 20.29% in 11- to 30-year-old subjects.2 Ganglioside GD1b levels are positively correlated with pilocytic astrocytoma tumor grade, and GD1b has been detected in various other gliomas, including primitive neuroectodermal tumors, glioblastomas, and anaplastic astrocytomas.3 This product contains ganglioside GD1b molecular species with primarily C18:0 fatty acyl chain lengths.
    Ganglioside GD1b Disodium Salt (Bovine Brain)
  • HY-135115
    Oleuropein Aglycone

    3,4-DHPEA-EA

    		 Others Inflammation/Immunology
    Oleuropein aglycone is a polyphenol and an aglycone form of Oleuropein (HY-N0292) that has been found in extra virgin olive oil and has diverse biological activities. It is formed from oleuropein via enzymatic, acidic, or acetyl hydrolysis. Dietary administration of oleuropein aglycone (50 mg/kg of food) increases the number of neuronal autophagic vesicles and reverses cognitive deficits in a TgCRND8 transgenic mouse model of Alzheimer’s disease. It also decreases cortical and hippocampal levels of histone deacetylase 2 (HDAC2) and restores long-term potentiation in the same model. Oleuropein aglycone increases urinary norepinephrine, as well as interscapular brown adipose tissue epinephrine and UCP1 protein levels, and decreases plasma leptin levels and total abdominal cavity adipose tissue weight in a rat model of high-fat diet-induced obesity. It also reduces lung neutrophil infiltration, lipid peroxidation, and IL-1β levels in a mouse model of carrageenan-induced pleurisy.
    Oleuropein Aglycone
  • HY-131682
    3-C6-NBD-cholesterol

    3-Hexanoyl-NBD-cholesterol

    		 Fluorescent Dye Others
    3-C6-NBD-cholesterol is a fluorescent analog of Chol that can be used to measure the kinetics of membrane and intracellular trafficking .
    3-C6-NBD-cholesterol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: